ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,459.10
      1.11%
      US Tech 100
      18,514.00
      1.00%
      Dow Jones
      40,589.34
      1.64%
      Brent Oil
      79.745
      0.00%
      Bitcoin
      68,438.60
      0.77%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Molecular Partners AG (MOLN) Quote

      Molecular Partners AG

      Molecular Partners AG (MOLN)

      NASDAQ
      6.3506
      0.4506
      (7.64%)
      Closed July 27 4:00PM
      Delayed by 15 minutes
      6.3506
      0.00
      (0.00%)
      After Hours: 6:41PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      6.3506
      Bid
      6.02
      Ask
      9.52
      Volume
      25,055
      5.805 Day's Range 6.71
      0.00 52 Week Range 0.00
      Market Cap
      230.872M
      Previous Close
      5.90
      Open
      6.43
      Last Trade
      4
      @
      6.3
      Last Trade Time
      Financial Volume
      $ 158,328
      VWAP
      6.3192
      Average Volume (3m)
      -
      Shares Outstanding
      36,354,297
      Dividend Yield
      -
      PE Ratio
      -3.45
      Earnings Per Share (EPS)
      -1.71
      Revenue
      7.04M
      Net Profit
      -61.98M

      About Molecular Partners AG

      Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseas... Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.molecularpartners.com
      Headquarters
      Schlieren, Che
      Founded
      1970
      Molecular Partners AG is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MOLN. The last closing price for Molecular Partners was $5.90. Over the last year, Molecular Partners shares have traded in a share price range of $ 0.00 to $ 0.00.

      Molecular Partners currently has 36,354,297 shares outstanding. The market capitalization of Molecular Partners is $214.49 million. Molecular Partners has a price to earnings ratio (PE ratio) of -3.45.

      MOLN Latest News

      More News

      Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

      ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

      June 17 2024
      GlobeNewswire Inc.

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      June 14 2024
      Edgar (US Regulatory)

      Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

      Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activatorsPreclinical safety, efficacy, and pharmacokinetics support MP0621’s...

      June 14 2024
      GlobeNewswire Inc.

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      June 11 2024
      Edgar (US Regulatory)

      Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

      MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in partnership with Orano MedPositive tumor to kidney ratio and biodistribution...

      June 11 2024
      GlobeNewswire Inc.

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      June 03 2024
      Edgar (US Regulatory)

      Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

      Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironmentFavorable and manageable safety profile observed at all tested dose...

      June 01 2024
      GlobeNewswire Inc.

      Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

      May 17 2024
      Edgar (US Regulatory)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      May 16 2024
      Edgar (US Regulatory)

      Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

      MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being preparedRadio-DARPin...

      May 16 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      WINTWindtree Therapeutics Inc
      $ 8.24
      (150.46%)
      		48.57M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NBSTWNewbury Street Acquisition Corporation
      $ 0.1349
      (92.71%)
      		122.1k
      YIBOPlanet Image International Ltd
      $ 2.915
      (53.43%)
      		260.07k
      CREVCarbon Revolution Public Ltd
      $ 9.00
      (45.87%)
      		8.06M
      NMHINatures Miracle Holding Inc
      $ 0.2035
      (-48.06%)
      		7.69M
      TANHTantech Holdings Ltd
      $ 0.2585
      (-47.23%)
      		6.75M
      DXCMDexCom Inc
      $ 64.00
      (-40.66%)
      		53.92M
      PSIGPS International Group Ltd
      $ 1.42
      (-31.40%)
      		716.26k
      POAIPredictive Oncology Inc
      $ 1.36
      (-27.27%)
      		6.02M
      SLNASelina Hospitality PLC
      $ 0.0305
      (-18.88%)
      		408.61M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NVDANVIDIA Corporation
      $ 113.06
      (0.69%)
      		293.33M
      SQQQProShares UltraPro Short QQQ
      $ 9.10
      (-2.88%)
      		176.49M
      SGMOSangamo Therapeutics Inc
      $ 0.8612
      (28.15%)
      		123.71M

      MOLN Discussion

      View Posts
      Monksdream Monksdream 3 weeks ago
      MOLN
      👍️0
      Awl416 Awl416 1 month ago
      Whoops
      👍️0
      TimeFades TimeFades 1 month ago
      Short
      👍️0
      Man6677 Man6677 3 years ago
      MOLN $$$$

      https://stockcharts.com/h-sc/ui?s=MOLN


      https://finance.yahoo.com/news/molecular-partners-finalizes-license-agreement-060000110.html

      GLTA !
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Molecular Partners shares are trading higher after the company, and Novartis, reported topline data from the Phase 2 study for ensovibep, a DARPin antiviral therapeutic for COVID-19.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
      👍️0

      Your Recent History

      NASDAQ
      MOLN
      Molecular Partners
      NASDAQ
      TPCS
      TechPrecision
      NYSE
      NP
      Neenah
      KOSDAQ
      318160
      Cell Bio Human Tech
      LATK
      KEYUSDT
      Selfkey
      BOV
      RNEW4
      RENOVA PN
      BIT
      UV4KR5
      Unicredit Bank
      Delayed Upgrade Clock